Targeted therapies for hepatocellular carcinoma Book Section
| Authors: | Feilchenfeldt, J. W.; O'Reilly, E. M.; Albany, C.; Abou-Alfa, G. K. |
| Editors: | McMasters, K. M.; Vauthey, J. N. |
| Article/Chapter Title: | Targeted therapies for hepatocellular carcinoma |
| Abstract: | The liver's role in xenobiotic metabolism, i.e., the modification of drugs and toxic foreign compounds, has long served as a putated explanation for inherent drug resistance of hepatocellular carcinoma (HCC). Therefore, it does not come as a surprise that the initial discovery of the multiple-drug resistance gene (MDR) was in liver tissue [1], and hepatocyte cell lines are a natural reservoir for the study of drug resistance. © 2011 Springer Science+Business Media, LLC. |
| Keywords: | sorafenib; bevacizumab; erlotinib; sunitinib; hcc etiology; hcc targeted therapies; tyrosine kinase inhibitors (tkis) |
| Book Title: | Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care |
| ISBN: | 978-1-60327-522-4 |
| Publisher: | Springer |
| Publication Place: | New York, NY |
| Date Published: | 2011-01-01 |
| Start Page: | 355 |
| End Page: | 368 |
| Language: | English |
| DOI: | 10.1007/978-1-60327-522-4_22 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | - Book Chapter 22 - 9781603275217 (ISBN) -- Export Date: 2 January 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work